Polyneuropathy Treatment Market

Polyneuropathy Treatment Market Outlook (2024 to 2034)

The global polyneuropathy treatment market size is valued at US$ 2.05 billion in 2024 and is projected to expand at a CAGR of 4.9% to reach US$ 3.31 billion by 2034-end.

Polyneuropathy is the simultaneous malfunction of several peripheral nerves throughout the body. Several agents or factors can cause polyneuropathy such as infections, drugs, toxins, cancers, diabetes, autoimmune disorders, nutritional deficiencies, HIV/AIDS, and some idiopathic factors. Effective treatment approaches for polyneuropathy are crucial to improving patient outcomes. The global landscape of polyneuropathy treatment involves various treatment options, reflecting medical science and technological advancements.

Increasing burden of polyneuropathy globally is supporting the demand for effective therapies. Factors such as the rising prevalence of diabetes and chronic infections, the increasing aging population, and poor lifestyle habits are primarily contributing to the growing incidence of polyneuropathy.

Prevalence of polyneuropathy is higher in elderly people. The need for sophisticated therapeutic strategies is being driven by the aging population's increasing prevalence of various chronic diseases. Additionally, more varied and potent treatment choices are projected to become available as a result of current research and development efforts in the treatment of autoimmune illnesses, diabetes, cancer, and HIV/AIDS infections.

• North America is projected to hold 37.2% of the global polyneuropathy treatment market share by 2034.
• Revenue from polyneuropathy therapeutics in Latin America is estimated at US$ 87.2 million for 2024.

Report Attributes	Details
Polyneuropathy Treatment Market Size (2024E)	US$ 2.05 Billion
Forecasted Market Value (2034F)	US$ 3.31 Billion
Global Market Growth Rate (2024 to 2034)	4.9% CAGR
United States Market Growth Rate (2024 to 2034)	4.8% CAGR
Chile Market Value (2034F)	US$ 35.3 Million
Key Companies Profiled	Pfizer Inc. Abbott Laboratories Johnson & Johnson (Janssen Global Services LLC) Lupin Limited Eli Lilly & Co. Glenmark Pharmaceuticals Ltd. Teva Pharmaceuticals Medtronic AbbVie Zydus Healthcare Ltd.

What are the Prominent Polyneuropathy Treatment Market Trends?

“Rising Prevalence of Diabetes and Other Chronic Infections and Poor Lifestyle Habits”

Prevalence of diabetes and chronic diseases is rapidly increasing across the world. Diabetes is considered the prime culprit for the development of peripheral neuropathy.

• The World Health Organization (WHO) reports that between 2000 and 2019, diabetes raised age-standardized death rates by 3%, while in lower-middle-income nations, diabetes increased mortality by 13%.

In diabetics and other individuals with reduced pain thresholds, self-care skills can reduce symptoms and create conditions that promote nerve regeneration. Precise blood glucose management can assist diabetic neuropathy patients in nerve damage treatment and lessen neuropathic symptoms.

• A United Nations research states that by 2030, the global burden of the disease is predicted to reach 56% and the percentage of fatalities worldwide attributable to chronic diseases is reaching 70%. The largest increases are forecasted for Africa and the Eastern Mediterranean regions.

Poor lifestyle habits such as excessive alcohol consumption and physical inactivity as well as vitamin deficiencies can cause nerve damage, which may lead to polyneuropathy. As alcohol is a neurotoxin, heavy drinking over a long period can significantly increase the risk of polyneuropathy. Deficiencies of essential vitamins like B1, B6, B12, and E can impact nerve function and contribute to polyneuropathy.

“Increasing Number of Pipeline Products for Treatment of Neuropathic Pain”

An increasing number of pipeline products for the treatment of various types of neuropathies is projected to drive market growth over the forecast period.

• The lead molecule WST-057 by Winsantor completed phase 1 and 2 clinical trials in 2023 and is currently in phase 3 clinical trials. It has shown positive results until now for regenerating peripheral nerves, particularly the axon terminals (intraepidermal nerve fiber [IENF]) for the treatment of diabetic peripheral neuropathy.
• In January 2023, the Salk Institute revealed that diabetic mice with low serine levels had a higher chance of developing peripheral neuropathy. These new findings could be used to look into the possibility of using serine supplementation as neuropathy medication to mitigate neuropathy symptoms.
• In September 2022, phase 2 clinical research was initiated to evaluate ATX01, or topical amitriptyline, developed by AlgoTx, for patients suffering from chemotherapy-induced peripheral neuropathy (CIPN). The study will be conducted in more than 40 locations across Europe and the United States.
• Positive outcomes from the Phase 2 CONVEY study of vixotrigine (BIIB074) were reported by Biogen Inc. in September 2021. In this research, the effect of non-opioid oral pain medication is being examined in the treatment of small fiber neuropathy (SFN).

What is Hampering the Market for Polyneuropathy Treatment?

“High Cost of Treatment and Associated Adverse Effects”

Therapies for neuropathy can be costly, especially the more advanced ones and surgical procedures. Patients with low incomes or insufficient insurance coverage may find it more difficult and expensive to receive care for undergoing several lines of treatment.

• In 2019 according to the survey of Neuragenex, peripheral neuropathy patients paid, on average, US$ 23,183 for the first line of therapy and
  US$ 37,880 for the second line of therapy. Healthcare professionals should avoid the trial-and-error phase wherever possible, given the potential cost implications of nerve pain medications.

Advanced treatment options such as transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS), and plasma exchange therapy are comparatively more expensive. Also, these drugs can have several side effects, such as headache, weight gain, nausea, skin rashes, or diarrhea. These symptoms are usually mild and temporary. Certain people may have daytime sleepiness after using antidepressants, which could disrupt their typical routine.

Which Key Strategies are Proving Instrumental for New Companies?

“Rising Investments in Medical R&D and Focus on Individualized Treatment”

A country's ability to innovate is fueled by its investments in R&D as well as the development of a workforce capable of performing technologically advanced tasks. New therapeutic approaches are projected to stand out for their innovative treatment approaches, which include neuroregeneration, gene therapy, stem cell therapy, and neuromodulation procedures. Patients and healthcare practitioners must pay attention to and support innovations that address unmet medical requirements or offer a more efficient and individualized approach to treatment.

Clinical trial participation and funding should be encouraged among new businesses. This might improve the company's reputation in addition to aiding in the creation of novel treatments. Successful trial results are forecasted to strengthen the case for regulatory approvals and promote confidence among medical professionals.

Collaborating with research centers and well-established entities can promote the sharing of knowledge and give access to supplementary skills. Partnerships also expedite research and development activities, allowing new manufacturers to more quickly introduce novel products to the market.

Country-wise Analysis

According to the analysis conducted by Fact.MR, a provider of competitive intelligence and market research, several factors, such as the existence of advanced healthcare systems, research initiatives, funding from the government, awareness campaigns, and patient access to cutting-edge therapies, are driving the growth of the markets in the United States and Germany. Markets in Japan and other Asia Pacific nations are also exhibiting growth.

Why are Polyneuropathy Drug Providers Focusing on the United States?

“Increasing Prevalence of Polyneuropathy Due to Poor Lifestyle Choices”

Attribute	United States
Market Value (2024E)	US$ 662.8 Million
Growth Rate (2024 to 2034)	4.8% CAGR
Projected Value (2034F)	US$ 1.05 Billion

Poor lifestyle choices, consumption of processed foods, improper nutrition, lack of exercise, and a rising aging population are the key elements primarily boosting the demand for effective therapeutic approaches in the United States. Increasing investments in research, well-developed healthcare infrastructure, the launch of novel therapies, and the rising number of product approvals from regulatory authorities are other factors that are providing opportunities to several polyneuropathy treatment companies in the country.

What is Complementing Market Growth in Germany?

“Emphasis on Research & Innovation and Collaborative Healthcare Ecosystem”

Germany's significant focus on medical innovation and research has placed it in a leadership position in the European healthcare sector. The market is growing at a very rapid pace due to the constant flow of discoveries driven by research, like treatments for polyneuropathy.

The country's cooperative healthcare system, which combines close ties between industry, academia, and healthcare practitioners, is also creating an environment that is favorable for the creation and uptake of treatments for polyneuropathy.

Will Japan be a Lucrative Market for Polyneuropathy Treatment Providers?

“Increased Public and Private Sector Investments in Providing Better Therapies”

Attribute	Brazil
Market Value (2024E)	US$ 103.2 Million
Growth Rate (2024 to 2034)	4.1% CAGR
Projected Value (2034F)	US$ 153.5 Million

Japan is a lucrative market for established as well as new providers of polyneuropathy treatment. Japan has a growing senescent population that is more prone to developing nerve pain due to several health-related issues. Increased investment by the public and private sectors to provide better treatment therapies to the elderly population in Japan is projected to lead to the expansion of the polyneuropathy treatment market size.

Category-wise Analysis

Diabetic polyneuropathy and chemotherapy-induced polyneuropathy are the primary types of neuropathies that are responsible for the polyneuropathy treatment market growth. Neuropathy drugs such as pregabalin, gabapentin, and serotonin and norepinephrine reuptake inhibitors (SNRIs) are used in first-line therapy of polyneuropathy treatment and generate the majority of market revenue.

Why are Therapies for Diabetic and Chemotherapy-induced Polyneuropathy Popular?

“Rising Prevalence of Diabetes and Cancer Worldwide”

Attribute	Diabetic Polyneuropathy
Segment Value (2024E)	US$ 883.4 Million
Growth Rate (2024 to 2034)	6.1% CAGR
Projected Value (2034F)	US$ 1.6 Billion

Attribute	Chemotherapy-induced Polyneuropathy
Segment Value (2024E)	US$ 667.8 Million
Growth Rate (2024 to 2034)	4.2% CAGR
Projected Value (2034F)	US$ 1 Billion

The market is divided into segments including diabetic polyneuropathy, chemotherapy-induced polyneuropathy, idiopathic polyneuropathy, HIV/AIDS-associated polyneuropathy, and autoimmune polyneuropathy, based on neuropathy type. The growing global prevalence of diabetes and cancer drives the rising demand for polyneuropathy treatment.

• According to the National Library of Medicine, 50% to 60% of patients with diabetes mellitus will eventually experience neuropathic pain during their lifetime.

Competitive Landscape

To increase their profits, key players in the polyneuropathy treatment market are focusing on tactics like enhanced research, strategic alliances, international market expansion, patient-centered care, regulatory competence, market-specific pricing plans, and technology integration. These diverse approaches guarantee that top businesses not only successfully negotiate the market's complexity but also foster innovation and make a significant contribution to the improvement of polyneuropathy treatment.

Key Segments of Polyneuropathy Treatment Market Research

• By Type :

  • Diabetic Polyneuropathy
  • Chemotherapy-induced Polyneuropathy
  • Idiopathic Polyneuropathy
  • HIV/AIDS-associated Polyneuropathy
  • Autoimmune Polyneuropathy

• By Treatment :

  • Drugs
    • Analgesics
      • Non-opioid Analgesics
      • Opioid Analgesics
    • Antidepressants
      • TCAs
      • SNRIs
      • SSRIs
    • Anticonvulsants / Antiepileptics
    • Other Drugs
  • Other Treatments
    • Transcutaneous Electrical Nerve Stimulation (TENS)
    • Plasma Exchange

• By Distribution Channel :

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies

• By Region :

  • North America
  • Latin America
  • Western Europe
  • East Asia
  • South Asia & Pacific
  • Eastern Europe
  • Middle East & Africa